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Abstract
Background and objectives: Testicular Leydig cell tumours (LCTs) are rare, steroid-secreting tumours.
Elevated levels of aromatase (CYP19 or CYP19A1) mRNA have been previously described in LCTs;
however, little is known about the mechanism(s) causing CYP19 over-expression. We report an LCT in
a 29-year-old male with elevated plasma oestradiol caused by enhanced CYP19 transcription.
Design and methods: First, we measured the intra-tumour expression of CYP19 and determined the use
of CYP19 promoters by qPCR. Secondly, we explored CYP19 and promoter II (PII) for gene
ampliﬁcations and activating mutations in PII by sequencing. Thirdly, we analysed intra-tumour
expression of steroidogenic factor 1 (SF-1 (NR5A1)), liver receptor homologue-1 (LRH-1 (NR5A2))
and cyclooxygenase-2 (COX2 (PTGS2)). Finally, we analysed SF-1 for promoter mutations and gene
ampliﬁcations.
Results: Similar to what has been recorded in normal Leydig cells, we ﬁrst found the bulk of tumour
CYP19 transcripts to be PII derived, excluding promoter shift as a cause of enhanced transcription.
Secondly, we excluded CYP19 and PII gene ampliﬁcations, and activating mutations in PII, as causes
of elevated CYP19 mRNA. We found SF-1 mRNA to be up-regulated in the tumour, while LRH-1 and
COX2 were down-regulated. The ﬁnding of elevated SF-1 levels in the tumour was conﬁrmed by
immunohistochemistry. The elevated level of SF-1 was not due to promoter mutations or
ampliﬁcations of the SF-1 gene.
Conclusions: Our results strongly suggest that the elevated levels of SF-1 have induced PII-regulated
CYP19 transcription in this tumour. These ﬁndings are of relevance to the understanding of CYP19
up-regulation in general, which may occur in several tissues, including breast cancer.
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Introduction
Leydig cells are found adjacent to the seminiferous
tubules in the testicles. These cells constitute the main
androgen-synthesising compartment in adult males
and are also capable of oestrogen production (reviewed
in (1, 2, 3, 4)).
Leydig cell tumours (LCTs) of the testis are rare,
representingabout 1–3% of all testicular tumours. They
are most frequently diagnosed in pre-pubertal boys
between 5 and 10 years and adult men aged 30–60
years (5, 6). While usually benign, about 10% of LCTs
in adult patients reveal a malignant phenotype (7).
LCTs are steroid-secreting tumours and con-
sequently associated with endocrine disturbances.
In testosterone-secreting LCTs, boys usually present
symptoms of precocious puberty, whereas excess
androgen rarely causes notable effects in adults. About
one-fourth of all LCTs are oestrogen secreting, and
the most common symptoms include gynaecomastia
in addition to sexual dysfunction and infertility in
adults (6, 8, 9, 10). There have also been described
cases of LCTs in pre-pubertal boys, revealing symptoms
of both oestrogen and androgen production, causing
gynaecomastia and precocious puberty in concert
(reviewed in (4)).
Local oestrogen synthesis plays a functional role
in the testis (reviewed in (11, 12)). In resemblance
with other oestrogen-producing compartments, andro-
gens are converted into oestrogens by the aromatase
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gene, localised at chromosome 15q21.2 (13, 14, 15).
The unusually large regulatory region of this gene
contains several tissue-speciﬁc promoters, and each of
the promoters give rise to mRNAs with distinct
untranslated ﬁrst exons (16). The ﬁrst exon is spliced
onto a common splice junction in exon II, immediately
upstream of the coding region. Thus, the different
mRNA species expressed from this gene contains an
identical open reading frame (exons II–X), and the
translated protein is the same, regardless of the
promoter used.
Elevated CYP19 expression with subsequent high
plasma oestradiol (E2) levels has been reported in a few
cases of testicular LCTs (17, 18, 19, 20, 21). The main
regulator of normal testicular cell aromatization is the
CYP19 proximal promoter II (PII), which has also been
reported as the main active promoter in LCTs (18, 20).
Different response elements have been identiﬁed in
PII, and both steroidogenic factor 1 (SF-1 (encoded by
NR5A1)) and liver receptor homologue-1 (LRH-1
(encoded by NR5A2)) have been reported to be involved
in PII-regulated CYP19 expression (22, 23, 24, 25).
Moreover, several cAMP-response element (CRE)-like
sequences have been identiﬁed in PII (26, 27), and
cyclooxygenase-2 (COX2 (encoded by PTGS2)) was
recently reported to be involved in the phosphorylation
of CRE-binding proteins and thus stimulate
CYP19 expression and the proliferation of Leydig
tumour cells (28).
While over-expression of SF-1 was reported in Fisher
rat testicular tumours (22), so far we lack information
regarding what mechanism(s) may cause CYP19 over-
expression in human testicular LCTs. Here, we report
an oestrogen-producing LCT in a 29-year-old man. The
ﬁnding of SF-1 over-expression in concert with elevated
levels of the PII-derived CYP19 transcripts suggests
increased SF-1 levels to play a key role in stimulating
oestrogen synthesis in these tumour cells.
Materials and methods
Patient
A 29-year-old male with severe gynaecomastia and
elevated plasma E2 levels (248 pM, normal upper range
130 pM) was referred to the Endocrine Unit. He was
subsequently diagnosed with an oestrogen-producing
LCT on the right testis. The tumour was not palpable
but visualised on testicular ultrasound. He had normal
pubertal growth, had developed normal secondary sex
characteristics and was the father of one child. There
was no clinical, biochemical (HCG and a-fetoprotein
negative) or radiological sign of malignant disease.
The high serum E2 levels returned to normal after
surgical removal of the tumour. Although E2, testoster-
one and SHBG levels normalised rapidly, LH and FSH
remained elevated at follow-up, indicating impaired
function of the left testicle. All serum hormone levels are
summarised in Table 1. At 1-year follow-up, he felt well
and the gynaecomastia had resolved.
Subject to patient consent, part of the tumour
specimen obtained at orchidectomy was snap-frozen
and stored in liquid nitrogen for research purposes.
Histology
A part of the testis specimen was ﬁxed in 4% formalin
and representative samples including both tumour and
normal tissues were embedded in parafﬁn. Standard
haematoxylin- and eosin (H&E)-stained sections (5 mm)
were made for microscopic histology evaluation.
Immunohistochemistry
Sections (5 mm) from formalin-ﬁxed, parafﬁn-embedded
tumours were prepared. Immunohistochemical aroma-
tase enzyme staining was performed using the MAB
Aro677 (gift from Dr Dean Evans, Novartis AG). SF-1
was stained with the mouse antihuman MAB 434200
(Invitrogen), while the oestrogen and progesterone
receptors (PRs) were stained using the MABs M7047
and M3659 (Dako, Glostrup, Denmark) respectively.
For the staining procedure, the DAKO Envision HRP
mouse kit (Dako) with DAB as detection method
was used.
RNA extraction and cDNA synthesis
Total RNA was extracted from snap-frozen biopsies
using Trizol reagent (Life Technologies) according to
the manufacturer’s procedure and dissolved in DEPC-
treated deionised water as described by Knappskog
et al. (29). The RNA concentration was measured on a
Nanodrop ND1000 spectrophotometer and adjusted to
1 mg/ml.
Single-strand cDNA was synthesised from 4 mg total
RNA using Transcriptor reverse transcriptase (Roche)
according to the manufacturer’s procedure. Both oligoT
(16-mers) and random hexamers were used as primers
in the cDNA synthesis reaction mix.
Table 1 Patient serum hormone levels (pmol/l).
Normal
Before
operation
1 Month
after
operation
1 Year
follow-up
S-oestradiol
(pmol/l)
20–130 248 112 124
S-testosterone
(nmol/l)
6.7–31.9 7.8 15.2 19.0
S-SHBG
(nmol/l)
13–71 50 40 41
S-LH (IE/l) 0.8–7.6 2.8 26.7 25.9
S-FSH (IE/l) 0.7–11.1 0.9 25.4 29.6
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Primers/probes Sequences
mRNA expression
Total CYP19 F5 0-ATCCTCAATACCAGGTCCTGGC
Total CYP19 R5 0-AGAGATCCAGACTCGCATGAATTCT
Total CYP19 probe 50-6FAM-ACCCGGTTGTAGTAGTTGCAGGCACT-BBQ
RPLP2 F5 0-GACCGGCTCAACAAGGTTAT
RPLP2 R5 0-CCCCACCAGCAGGTACAC
RPLP2 probe 50-Cy5-AGCTGAATGGAAAAAACATTGAAGACGTC-BBQ
CYP19_exon1.3 F 50-GTCTAAAGGAACCTGAGACTCTACC
CYP19_exon1.4 F 50-CACTGGTCAGCCCATCAA
CYP19_exon1.7 F 50-AGAAAGGGGTGAAATCAGCAA
CYP19_exon1 common R 50-ACGATGCTGGTGATGTTATAATGT
CYP19_exon1 common probe 50-6FAM-TCGGGTTCAGCATTTCCAAAACCAT-BBQ
CYP19_exonII F 50-CCCTTTGATTTCCACAGGAC
CYP19_exon3 R 50-CCCATGCAGTAGCCAGGAC
CYP19_exonII probe 50-6FAM-CATGCCAGTCCTGCTCCTCA-BBQ
COX2 F5 0-ATCACAGGCTTCCATTGACC
COX2 R5 0-CAGGATACAGCTCCACAGCA
COX2 probe 50-6FAM-CCGCAAACGCTTTATGCTGA-BBQ
SF-1 F5 0-TCATCCTCTTCAGCCTGGAT
SF-1 R5 0-AGGTACTCCTTGGCCTGCAT
SF-1 probe 50-6FAM-ACGCTCAGGAGAAGGCCAAC-BBQ
LRH-1 F5 0-GCACAGGAGTTAGTGGCAAA
LRH-1 R5 0-CTGCTGCGGGTAGTTACACA
LRH-1 probe 50-6FAM-AACAAGTCAATGCCGCCCT-BBQ
Gene copy number analysis
CYP19 gDNA F1 50-TTATGGGAGCCTGGTAGTGG
CYP19 gDNA R1 50-AGGGTGGGGTTTTCTATTGG
CYP19 gDNA probe 1 50-6FAM-TTGGAACATCATACCCCGGG-BBQ
CYP19 gDNA F2 50-GGTGGCTTTTGCTGATCAAT
CYP19 gDNA R2 50-AGAAAATGGGCACGAAACTG
CYP19 gDNA probe 2 50-6FAM-AGCTCCTGCCAGCTCCCTTT-BBQ
CYP19 PII gDNA F1 50-TTGGTCAAAAAAGGGGAGTTG
CYP19 PII gDNA R1 50-ATCATCTTGCCCTTGAGTGG
CYP19 PII gDNA F2 50-TCCACCTCTGGAATGAGCTT
CYP19 PII gDNA R2 50-TTGCAGCATTTCTGACCTTG
CYP19 PII gDNA probes 1 and 2 50-6FAM-CTTTCAATTGGGAATGCACG-BBQ
CYP19 PII gDNA F3 50-GGGCTTCCTTGTTTTGACTT
CYP19 PII gDNA R3 50-GAGGGGGCAATTTAGAGTCC
CYP19 PII gDNA probe 3 50-6FAM-CACCCTCTGAAGCAACAGGA-BBQ
B2M gDNA F 50-CATCCAGCAGAGAATGGAAAG
B2M gDNA R 50-GAAAGACCAGTCCTTGCTGAA
B2M gDNA probe 50-Cy5-TGGGTTTCATCCATCCGACA-BBQ
PCR/sequencing of CYP19 PII and SF-1 promoter area
CYP19 PII PCR F1 CTCAACGATGCCCAAGAAAT
CYP19 PII PCR R1 CATGGACCAAAATCCCAAGT
CYP19 PII Seq F2 TTGGTCAAAAAGGGGAGTTG
CYP19 PII Seq R2 CTTACCTGGTATTGAGGATGTGC
CYP19 PII Seq F3 GGCAAGAAATTTGGCTTTCA
CYP19 PII Seq R3 GAGGGGGCAATTTAGAGTCC
SF-1 F2 TCTGCCTCCCAGGTTCAAGC
SF-1 R8 GGTGACTGGATCTTTTGTGTGTTCCTC
SF-1 F4 GAGGAACACACAAAAGATCCAGTCACC
SF-1 R7 CTTGGCCAGCTGGCTGTTG
SF-1 F6 TGTCCTGACTCTACTCCAATGTCCG
SF-1 R2 AACCCCTGAGAAACAAGAGCATCTG
SF-1 R9 (seq) TGTGTGTGTTCCTCTGTTTGTCTCAC
SF-1 R10 (seq) GGGCTTGATTTATGGGCTGCTC
SF-1 F6 (seq) TGTCCTGACTCTACTCCAATGTCCG
SF-1 F8 (seq) CACCAACAAAGAAGGCGAGAGG
SF-1 F9 (seq) TCTGTCCCCCACCTGAGTTTC
SF-1 F10 (seq) CCACTGCCACCCTCATCC
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Genomic DNA was extracted from snap-frozen biopsies
using QIAamp DNA Mini Kit (Qiagen) according to the
manufacturer’s procedure.
Quantitative PCR
Transcript levels of total CYP19, promoter-speciﬁc
CYP19 transcript variants, COX2, SF-1 and LRH-1,
were quantiﬁed using the Lightcycler 480 instrument
(Roche). Ribosomal protein P2 (RPLP2) mRNA level
was used as reference. The ampliﬁcation primers and
BlackBerry-quenched hydrolysis probes used are listed
in Table 2.
Ampliﬁcation was performed in a 20 ml reaction
solution using the LC480 Probes Master (Roche)
reaction mix, 0.5 mM of each primer, 0.125 mM
hydrolysis probe and 0.5 ml cDNA synthesised from
4 mg total RNA. The following thermocycling conditions
were used: initial denaturation/enzyme activation at
95 8C for 5 min and then 50 cycles of 95 8C for 10 s
(denaturation) and 55 8C for 20 s (annealing/elonga-
tion) before a ﬁnal cooling step at 40 8C for 5 s. Negative
controls (water) were included in each run.
The results were converted into relative concen-
trations using an in-run standard curve, and then
normalised for RPLP2 mRNA levels. All gene-speciﬁc
data from the tumour sample were compared with the
corresponding data from a reference sample consisting
of pooled total RNA from healthy testis of ﬁve donors
(BioChain, Newark, CA, USA).
The expression levels of the promoter-speciﬁc tran-
script variants were assessed using different primers and
assay-speciﬁc standard curves (i.e. different qPCR
efﬁciencies), and the data are therefore not directly
comparable. However, an estimate of the differences in
expression of these promoters can be made by assuming
that all reactions run with the same efﬁcacy (efﬁ-
ciencyZ2) and comparing the delta crossing points of
the different assays.
Gene copy number analysis (qPCR)
In order to investigate possible gene copy number
changes of the CYP19 gene and the CYP19 PII, levels of
genomic DNA were quantiﬁed in duplex reactions with
beta-2-microglobulin (B2M) as reference using the
Lightcycler 480 instrument (Roche). Two distinct
CYP19 genomic areas and three distinct areas
covering the CYP19 PII region were ampliﬁed using
the primers and BlackBerry-quenched hydrolysis
probes listed in Table 2. Ampliﬁcation was performed
in a 20 ml reaction solution using the LC480 Probes
Master (Roche) reaction mix, 0.5 mM of each primer,
0.125 mM of each hydrolysis probe and 2 ml gDNA as
template. The following thermocycling conditions were
used: initial denaturation/enzyme activation of 95 8C
for 5 min and then 50 cycles of 95 8Cf o r1 5 s
(denaturation) and 55 8C for 20 s (annealing/elonga-
tion) before a ﬁnal cooling step at 40 8C for 5 s. Negative
controls (water) were included in each run. The data
obtained through quantiﬁcation were normalised by
adjusting for B2M levels. These normalised values were
divided by the corresponding values from a reference
sample (pooled DNA from six healthy donors). The
concentration of the reference was set to 1.0, and we
considered the samples to have reduced copy number if
the sample/reference ratio was !0.65 and increased
copy number if the ratio was O1.35.
PCR ampliﬁcation and sequencing
The CYP19 PII and SF-1 promoter regions were
ampliﬁed and sequenced using primers listed in
Table2.TheSF-1genehastwoalternative,untranslated
ﬁrst exons. Relative to the transcription start sites of
thesetwoexons,wesequencedtheareaK1475/C1053
(alternative 1) and K1650/C858 (alternative 2).
PCR ampliﬁcation was performed using the Kod XL
DNA polymerase system (Merck) in a 50 ml reaction mix
containing 1! PCR buffer, 0.2 mM of each deoxynu-
cleotide triphosphate, 0.2 mM of each primer, 1.25 U
Kod XL DNA polymerase and 1 ml genomic DNA. The
thermocycling conditions used were an initial
denaturation step of 5 min at 94 8C, followed by 30
cycles of denaturation (94 8C for 1 min), annealing
(CYP19 PII: 54.9 8C and SF-1: 63.2 8C for 10 s) and
elongation (72 8C for 30 s) and a ﬁnal elongation step of
7m i n a t 7 28C. Following ampliﬁcation, the PCR
product was treated with ExoSAP-IT (USB Products,
Affymetrix, Inc., Santa Clara, CA, USA) at 37 8C for
30 minand80 8Cfor15 minaccordingtotheprocedure
as outlined by the manufacturer. DNA sequencing
was performed in a 10 ml reaction mix containing 1!
Figure 1 Standard H&E-stained section (5 mm) of testicular Leydig
cell tumour. The intra-testicular tumour (largest diameter of 1.8 cm)
was sharply delimited from the testicular parenchyma. The tumour
cells had abundant, deeply acidophilic, ﬁnely vacuolised cytoplasm
with focally deposited brownish yellow lipochrome pigment and
intracytoplasmic Reinke’s crystalloids. Scale barZ50 mm.
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(Applied Biosystems, Carlsbad, CA, USA). Capillary
electrophoresis was performed on an automated DNA
sequencer (ABI 3730).
Multiplex ligation-dependent probe
ampliﬁcation
The multiplex ligation-dependent probe ampliﬁcation
(MLPA) method and the SALSA MLPA kit P185-B1 lot
0308 (MRC Holland, Amsterdam, The Netherlands)
were used according to the manufacturer’s instructions
to identify deletions or ampliﬁcations in the SF-1 gene
(NR5A1) localised on 9q33.3. Capillary electrophoresis,
data collection and peak analysis were performed on an
automated DNA sequencer (ABI 3730). In the patient
sample, the peak areas of all MLPA products resulting
from SF-1-speciﬁc probes were ﬁrst normalised by the
average of peak areas resulting from control probes
speciﬁc for locations other than on chromosome
9q33.3. A ratio was then calculated where this
normalised value was divided by the corresponding
value from a sample consisting of pooled DNA from six
healthy individuals. A sample was scored as having a
reduced copy number at a speciﬁc location if this ratio
was below 0.75 and as having an increased copy
number if the ratio was above 1.25.
Results
Histology
The intra-testicular tumour (largest diameter of 1.8 cm)
was sharply delimited from the testicular parenchyma
with a non-inﬁltrative ‘pushing’ border and a solid/
nodular growth pattern. The tumour cells had
abundant, deeply acidophilic, ﬁnely vacuolised cyto-
plasm with focally deposited brownish yellow lipo-
chrome pigment and intracytoplasmic Reinke’s
crystalloids, as displayed by H&E staining in Fig. 1.N o
malignant histological features were observed, i.e.
tumour diameter !5 cm, lack of inﬁltrating border,
few mitoses (mean 1 per 10 high power ﬁelds), absence
of necrosis, no vascular invasion and low tumour cell
proliferation assessed with Ki-67/MIB-1 (1–2%). Immu-
nohistochemically, vimentin and inhibin were strongly
co-expressed and cytokeratin AE1/3 showed weak and
focal positivity, typical for this entity. The epithelial
marker (EMA) and germ cell markers (AFP, PLAP) were
negative. PRwas weakly positive in about 5% of tumour
nuclei and oestrogen receptor alpha (ERa) was negative.
CYP19 expression level in the tumour tissue
We examined the CYP19 expression level and found it
to be strongly up-regulated (125-fold) in the tumour
sample compared with normal testis tissue (Fig. 2A).
Then, we determined promoter usage by quantifying
CYP19 transcript variants speciﬁc for promoter PII, 1.3,
1.4 and 1.7 in both tumour and normal tissues (Fig. 2B,
C, D and E). The expression level of the PII-speciﬁc
CYP19 transcript in the tumour sample was 59-fold
elevated relative to normal testis tissue. In addition, we
found the transcript variants speciﬁc for promoters 1.3
and 1.7 to be up-regulated in the tumour tissue. The
transcript related to promoter 1.3 displayed an 11-fold
increase from normal to tumour tissue while the levels
of the variant speciﬁc for promoter 1.7 became
detectable in the tumour sample contrasting undetect-
able levels (after 50 ampliﬁcation cycles) in the normal
sample. Interestingly, the transcript variant speciﬁc for
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Figure 2 mRNA levels of total CYP19 and CYP19 promoter-speciﬁc
transcript variants. Transcript levels of total aromatase (CYP19)a n d
promoter-speciﬁcCYP19transcript variants weredeterminedinboth
tumour (T) and normal (N) testes with qPCR. Triplicate runs were
performed, and expression of the ribosomal protein P2 (RPLP2)w a s
used as reference in all the reactions. Individual in-run standard
curves were used in the ﬁve different assays and the relative
concentrations as displayed on the y-axes are therefore not
comparable between the assays A, B, C, D and E. We observed
an increased transcript level of (A) total CYP19 (125-fold),
(B) promoter II-speciﬁc CYP19 (59-fold), (C) promoter 1.3-speciﬁc
CYP19(11-fold)and(E)promoter1.7-speciﬁcCYP19(notdetectedin
the normal sample). (D) We observed a down-regulation of promoter
1.4-speciﬁc CYP19 transcript level (tumour to normal ratio: 0.4).
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(tumour to normal tissue ratio: 0.4).
Three runs were performed per promoter assay, and the
curves shown in Fig. 3 are representative for these runs.
The curves for RPLP2 were removed from Fig. 3 for clarity.
WhenassumingthattheqPCRsrunwiththesameefﬁcacy,
we found the tumour CYP19 mRNA levels deriving from
promoter PII to be 77-, 1233- and 7236-fold higher than
from promoters 1.3, 1.7 and 1.4 respectively.
This ﬁnding strongly indicates that PII-transcribed
mRNA accounts for the majority of the total CYP19
mRNA detected. Moreover, this ﬁnding reveals PII to be
the principal promoter in both normal and tumour
tissue, arguing against the use of an alternative
promoter as an explanation for elevated CYP19 levels.
CYP19 coding region and PII gene copy
number
Addressing the potential causes for CYP19 over-
expression, we analysed the gene copy number for
CYP19 using qPCR. No ampliﬁcations within the
CYP19 locus were observed.
In addition, due to the large contribution from PII, we
speculated whether CYP19 up-regulation could be due
to either a selective ampliﬁcation of the PII area or to an
activating mutation located in this promoter area.
Hence, we performed a copy number analysis speci-
ﬁcally for the region harbouring this promoter and
sequenced the PII region. No promoter ampliﬁcation,
mutations or polymorphisms were detected.
CYP19 protein staining
In order to validate the data obtained by qPCR, we
analysed CYP19 at the protein level by immunohis-
tochemistry (IHC). Anti-CYP19 (Aro 677)-stained
sections revealed focal strong cytoplasmic staining of
tumour Leydig cells and negative staining of normal
tissue sections (Fig. 4).
The transcription factor SF-1 is up-regulated
in the tumour
Based on the lack of copy number changes within the
CYP19 gene and PII, and/or mutations in PII,w e
hypothesised that the CYP19 over-expression could be
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Figure 3 qPCR-crossing points (Cps) for total CYP19 and CYP19
promoter-speciﬁc transcript variants. The qPCR-Cp values for each
of the promoters examined were compared in a common run. Three
runs were performed per promoter assay, and the curves shown
here are representative for these runs. All CYP19 assays were run
with RPLP2 as a reference; however, the curves for RPLP2 were
removed from the ﬁgure for clarity. The Cps strongly indicated that
the main contribution to the total CYP19 mRNA level was from PII.
(A) Tumour sample, (B) normal tissue sample.
A
B
Figure 4 Anti-CYP19 staining of tumour and normal tissue. Anti-
CYP19 (Aro 677) stained sections showed (A) strong cytoplasmic
staining for tumour Leydig cells, and (B) negative staining in normal
tissue. Scale bar: 100 mm.
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Regarding the structure of PII and its known binding
sites for different transcription factors, we analysed the
mRNA levels of three potential ligand candidates: COX2,
LRH-1 and SF-1. COX2 and LRH-1 were down-
regulated in the tumour compared with normal tissue
(tumour to normal ratios of 0.04 and 0.08 respectively).
In contrast, we found the mRNA level of SF-1 to be 6.6-
fold up-regulated in the tumour tissue compared with
the normal sample (Fig. 5).
In order to validate the data obtained by qPCR, we
analysed SF-1 at the protein level by IHC. Anti-SF-1-
stained sections showed strong nuclear staining in
tumour tissue and negative staining in normal tissue
(Fig. 6).
Finally, we explored potential causes of SF-1 over-
expression by analysing the copy number of this gene
using MLPA, as well as sequencing the promoter region
for potential activating mutations. No promoter
mutations, ampliﬁcations or deletions of SF-1 were
observed.
Discussion
While most LCTs reveal benign characteristics, the
elevated steroid production may cause disturbing
virilising or feminising symptoms.
In this report, we describe a patient with an
oestrogen-producing LCT revealing elevated CYP19
and SF-1 mRNA levels. While some previous papers
reported elevated oestrogen production in LCTs to be
related to enhanced CYP19 mRNA levels (17, 18, 19,
20, 21), the underlying cause of elevated CYP19 mRNA
in these tumours has not been reported so far. The
results presented here provide further insight into the
mechanism(s) of CYP19 up-regulation in LCTs.
First, we ruled out gene ampliﬁcation of the CYP19
gene as a potential cause of mRNA up-regulation.
Secondly, we evaluated the use of CYP19 promoters.
While the CYP19 enzyme is coded for by a single gene,
it is subject to tissue-speciﬁc regulation due to several
alternative promoters (16). Further, there is evidence
that CYP19 expression may be differentially regulated
in tumours compared with their normal tissue of origin.
Taking breast cancer as an example, CYP19 transcrip-
tion in normal breast tissue is mainly regulated by
promoter 1.4, while transcription in breast cancer
tissue is regulated by the promoters II, 1.3, 1.7 and 1.4
(30). Here, we found that the majority of the CYP19
mRNA transcripts in both normal and tumour tissue
originate from PII. Thus, the elevated CYP19 mRNA
level observed in the tumour tissue was not due to
alternative promoter use, in conformity with what has
been described earlier in a few other cases (18, 20).
Thirdly, we measured intra-tumour mRNA levels of
the ligands SF-1, LRH-1 and COX2. We found elevated
mRNA levels of SF-1 in tumour compared with normal
tissue, a ﬁnding validated by the observation of elevated
SF-1 protein staining by IHC. While our results are in
accordance with ﬁndings in experimental systems (22),
to the best of our knowledge, SF-1 up-regulation in
LCTs has not been demonstrated in humans earlier.
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Figure 5 The mRNA levels of SF-1, COX2 and LRH-1 (tumour/
normal tissue ratio) were analysed by qPCR. COX2 and LRH-1
were down-regulated in the tumour compared with normal tissue
(tumour to normal ratios of 0.04 and 0.08 respectively). In contrast,
we found the mRNA level of SF-1 to be 6.6-fold up-regulated in the
tumour tissue compared with the normal sample.
A
B
Figure 6 Anti-SF-1 staining of tumour and normal tissue. Anti-SF-1-
stained sections showed strong nuclear staining in tumour tissue
(A) and negative staining in normal tissue (B). Scale bar: 100 mm.
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due to NR5A1 gene ampliﬁcation nor due to activating
mutations in the promoter area. Moreover, we found the
expression of LRH-1 and COX2 to be signiﬁcantly down-
regulated in tumour tissue compared with normal
tissue. LRH-1, like SF-1, has been demonstrated to bind
a nuclear receptor half site in PII (31) and regulate
CYP19 expression in Leydig cells (23, 25).O u r
observation of SF-1 up-regulation in concert with
LRH-1 down-regulation might indicate that there is a
negative feedback loop controlling the expression of
these genes.
In previous studies, local COX2 up-regulation has
been discussed as a potential mechanism of elevated
oestrogen synthesis in inﬂammation and some cancers
(reviewed in (32)), but we lack evidence conﬁrming this
in vivo. To the best of our knowledge, this is the ﬁrst
report to demonstrate a similar effect on oestrogen
synthesis through local SF-1 up-regulation.
In summary, we found elevated oestrogen synthesis
in an LCT to be caused by elevated PII-transcribed
CYP19 levels. Moreover, we found the enhanced CYP19
transcription to be most likely caused by elevated levels
of the transcription factor SF-1. Interestingly, CYP19
up-regulation in oestrogen-dependent breast cancer has
been attributed to enhanced PII activity (30).O u r
ﬁndings reveal pathological SF-1 up-regulation to be a
potential mechanism enhancing local oestrogen
synthesis in LCTs, suggesting this mechanism to be
explored as a potential cause of CYP19 up-regulation in
other pathological conditions as well.
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